Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Oral arsenic for the treatment of APL in China

Hong-Hu Zhu • 25 Feb 2019
ISAL 2019
Acute Promyelocytic Leukemia Leukemia Rare Diseases All-trans retinoic acid Arsenic trioxide

Hong-Hu Zhu, MD, PhD, of The First Affiliated Hospital, Zhejiang University, Hangzhou, China, discusses the use of oral arsenic for the treatment of acute promyelocytic leukemia (APL) in China. Previous intravenous formulations of arsenic trioxide and all-trans retinoic acid (ATRA) meant that patients were required to visit the hospital for treatment. Now patients can complete post-remission treatment at home, greatly improving their quality of life. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Hong-Hu Zhu

1:27
MRD detection for AML in China & MFC to detect CEPBA mutations
Hong-Hu Zhu • 25 Feb 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals